Evidence map›Paper›PMID 40611132›Full record

ArticleJournal of translational medicine2025

Role of senescent CD4

Zhaoyuan Liang, Hua Zhang, Lu Xu, Nan Li, Zhongnan Yin, Yongchang Sun, Ning Shen, Zhengyang Guo, Yuqing Wang, Lixiang Xue and 4 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhaoyuan Liang *Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Hua Zhang *Research Center of Clinical Epidemiology, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Lu Xu *Research Center of Clinical Epidemiology, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Nan LiResearch Center of Clinical Epidemiology, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Zhongnan YinBiobank, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Yongchang SunDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.
Ning ShenDepartment of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.
Zhengyang GuoCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Yuqing WangCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Lixiang XueCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.
Jie ZhangCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China. zhangdiaojie@163.com.
Lin ZengResearch Center of Clinical Epidemiology, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China. zlwhy@163.com.
Jianling YangCenter of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China. jianlingyang@pku.edu.cn.ORCID 0000-0002-8879-6431
Siyan ZhanResearch Center of Clinical Epidemiology, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, 100191, China.

Funding

Beijing Key Clinical Specialty Construction, General Program of National Natural Science Foundation of China 82072870Clinical Cohort Construction Program of Peking University Third Hospital BYSYDL2023001Innovation and Transformation Fund of Peking University Third Hospital BYSYZHKC2022110Peking University Third Hospital Clinical Key Project BYSY2022069Youth Program of National Natural Science Foundation of China 81901570Youth Program of National Natural Science Foundation of China 82303801
6 · The paper itself

Abstract

backgroundIn late 2022, Beijing, China saw a large-scale BF.7 Omicron variant breakthrough infection. However, the impact of COVID-19 vaccines on elderly breakthrough-infected patients' antibodies and immune cells response was unclear.

methodsWe recruited 329 inpatients over 65 with BF.7 breakthrough infections. We analyzed the link between vaccination and survival in 67 sampled patients, investigating changes in antibody levels, cytokine profiles, as well as immune phenotypes.

resultsExperiments revealed that while vaccination could raise antibody levels in the elderly, it showed no significant neutralizing activity against the emerging COVID-19 variant XBB. Flow cytometry showed vaccination increased the proportion of CD4

conclusionsWe found the immunological efficacy of inactivated vaccines in elderly patients is influenced by the proportion of CD4

Indexed as

CD4-Positive T-LymphocytesCellular SenescenceCOVID-19SARS-CoV-2AgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsChinaCOVID-19 VaccinesFemaleHumansMaleVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID40611132
PMCPMC12232197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.